News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,774 Results
Type
Article (13950)
Company Profile (304)
Press Release (247520)
Section
Business (79358)
Career Advice (151)
Deals (13191)
Drug Delivery (34)
Drug Development (50332)
Employer Resources (31)
FDA (5682)
Job Trends (5116)
News (144139)
Policy (10018)
Tag
Academia (901)
Alliances (21527)
Alzheimer's disease (759)
Approvals (5665)
Artificial intelligence (69)
Bankruptcy (97)
Best Places to Work (4522)
Biotechnology (249)
Breast cancer (109)
Cancer (892)
Cardiovascular disease (71)
Career advice (132)
CAR-T (73)
Cell therapy (217)
Clinical research (40147)
Collaboration (311)
Compensation (129)
COVID-19 (1006)
C-suite (79)
Cystic fibrosis (67)
Data (984)
Diabetes (87)
Diagnostics (1207)
Drug discovery (57)
Earnings (29007)
Events (47198)
Executive appointments (249)
FDA (6055)
Funding (309)
Gene editing (63)
Gene therapy (163)
GLP-1 (311)
Government (1065)
Healthcare (6544)
Infectious disease (1044)
Inflammatory bowel disease (98)
IPO (7198)
Job creations (859)
Job search strategy (127)
Layoffs (188)
Legal (1375)
Lung cancer (131)
Lymphoma (62)
Manufacturing (87)
Medical device (2559)
Medtech (2560)
Mergers & acquisitions (6129)
Metabolic disorders (262)
Neuroscience (1003)
NextGen Class of 2024 (2004)
Non-profit (847)
Northern California (1094)
Obesity (142)
Opinion (91)
Parkinson's disease (78)
Patents (63)
People (25108)
Phase I (14155)
Phase II (18668)
Phase III (11820)
Pipeline (367)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (204)
Real estate (1409)
Regulatory (8289)
Research institute (931)
Southern California (981)
Startups (1964)
United States (8701)
Vaccines (165)
Weight loss (84)
Date
Today (65)
Last 7 days (354)
Last 30 days (1437)
Last 365 days (20591)
2024 (20503)
2023 (22413)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16926)
Australia (2856)
California (2484)
Canada (813)
China (204)
Colorado (92)
Connecticut (104)
Europe (36448)
Florida (273)
Georgia (71)
Illinois (154)
Indiana (61)
Maryland (334)
Massachusetts (1959)
Michigan (58)
Minnesota (101)
New Jersey (635)
New York (688)
North Carolina (420)
Northern California (1094)
Ohio (82)
Pennsylvania (476)
South America (207)
Southern California (981)
Texas (280)
Washington State (249)
261,774 Results for "aevitas therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H
Aevitas Therapeutics, Inc. today announced the execution of an asset purchase agreement for 4DMT to acquire Aevitas’ proprietary rights to its short-form human complement factor H (“sCFH”) asset for the treatment of complement-mediated diseases.
April 24, 2023
·
8 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Business
Aevitas Therapeutics Appoints Markus Peters, Ph.D., M.Sc., as Chief Executive Officer
Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company focused on the development of novel gene therapy approaches for complement-mediated diseases, today announced the appointment of Markus Peters, Ph.D., M.Sc., as President and Chief Executive Officer.
February 22, 2021
·
8 min read
Regulatory
FDA Warns Applied Therapeutics of ‘Objectionable Conditions’ in Govorestat Study
The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.
December 4, 2024
·
2 min read
·
Tristan Manalac
Press Releases
NeuroEM Therapeutics(R) Accepted into StartUp Health’s Alzheimer’s Moonshot Community(TM)
September 19, 2024
·
4 min read
Press Releases
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
December 18, 2024
·
16 min read
Complete response letters
Applied Therapeutics Crashes After FDA Rejection of Rare Disease Drug
After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ govorestat for galactosemia, citing “deficiencies” with the application. The biotech plans to meet with the regulator to discuss the best way forward for the drug.
December 2, 2024
·
3 min read
·
Tristan Manalac
Layoffs
Spero Therapeutics to Lay Off 39% of Employees
Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.
October 30, 2024
·
1 min read
·
Angela Gabriel
Deals
4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy
4D Molecular Therapeutics (Nasdaq: FDMT, “4DMT”), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large-market diseases, today announced that it acquired the rights and know-how for short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.
April 24, 2023
·
8 min read
Layoffs
Viracta Therapeutics Cuts 42% of Staff as Part of Resource Reprioritization
Following two layoffs in less than three months, Viracta Therapeutics may have around 18 employees left to advance its efforts to bring lead product candidate nana-val to market.
November 7, 2024
·
2 min read
·
Angela Gabriel
1 of 26,178
Next
